A clinical and economic analysis of the use of dapagliflozin in patients with chronic heart failure in the entire spectrum of left ventricular ejection fraction in the Russian Federation

Cover Page

Cite item

Full Text

Abstract

Aim. To estimate the cost-effectiveness of dapagliflozin across the range of ejection fraction in patients with heart failure (HF) in Russian Federation.

Materials and methods. Cost-effectiveness model was developed for estimate the use of dapagliflozin as part of standard therapy in patients with HF regardless of ejection fraction is unknown. The calculation of costs was carried out in a mathematical model adapted to the conditions of Russian healthcare system by using Russian costs inputs and patient population characteristics.

Results. In the model, dapagliflozin therapy yielded a mean of 0.209 additional life-years compared with standard of care in 10 years horizon. The incremental cost of 1 additional life-year was 665,715 RUB, which does not exceed the threshold of willingness to pay 2,235,202 RUB.

Conclusion. Thus, the intensification of chronic HF therapy with dapagliflozin is cost effective. The use of dapagliflozin in a cohort of 1000 target patients over 10 years will avoid 146 hospitalizations and 39 emergency visits due to HF, as well as prevent 32 deaths from cardiovascular diseases.

About the authors

Sergey V. Nedogoda

Volgograd State Medical University

Email: salasyukas@outlook.com
ORCID iD: 0000-0001-5981-1754

Doctor of Medical Sciences, Professor, Head. Department Institute of Continuing Medical and Pharmaceutical Education of Internal Medicine

Russian Federation, Volgograd

Sergey N. Tereshchenko

Chazov National Medical Research Center of Cardiology; Russian Medical Academy of Continuous Professional Education

Email: salasyukas@outlook.com
ORCID iD: 0000-0001-9234-6129

Doctor of Medical Sciences, Professor, Head of the Department of Myocardial Diseases and Heart Failure, Head of the Department of Cardiology

Russian Federation, Moscow; Moscow

Igor V. Zhirov

Chazov National Medical Research Center of Cardiology; Russian Medical Academy of Continuous Professional Education

Email: salasyukas@outlook.com
ORCID iD: 0000-0002-4066-2661

Doctor of Medical Sciences, Ved. Researcher at the Department of Myocardial Diseases and Heart Failure, Professor at the Department of Cardiology

Russian Federation, Moscow; Moscow

Alla S. Salasyuk

Volgograd State Medical University

Author for correspondence.
Email: salasyukas@outlook.com
ORCID iD: 0000-0002-6611-9165

Doctor of Medical Sciences, Professor of the Department of Internal Medicine of the Institute of Continuing Medical and Pharmaceutical Education

Russian Federation, Volgograd

Irina N. Barykina

Volgograd State Medical University

Email: salasyukas@outlook.com
ORCID iD: 0000-0002-7061-6164

Candidate of Medical Sciences, Associate Professor department Institute of Continuing Medical and Pharmaceutical Education of Internal Medicine

Russian Federation, Volgograd

Viktoria O. Lutova

Volgograd State Medical University

Email: salasyukas@outlook.com
ORCID iD: 0000-0002-0646-5824

Candidate of Medical Sciences, Assistant at the Department of Internal Medicine, Institute of Continuing Medical and Pharmaceutical Education

Russian Federation, Volgograd

Ekaterina A. Popova

Volgograd State Medical University

Email: salasyukas@outlook.com
ORCID iD: 0000-0002-3498-7718

assistant department Institute of Continuing Medical and Pharmaceutical Education of Internal Medicine

Russian Federation, Volgograd

References

  1. Фомин И.В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016;(8):7-13 [Fomin IV. Chronic heart failure in Russian Federation: what do we know and what to do. Russian Journal of Cardiology. 2016;(8):7-13 (in Russian)]. doi: 10.15829/1560-4071-2016-8-7-13
  2. Lytvyn Y, Bjornstad P, Udell JA, et al. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials. Circulation. 2017;136(17):1643-58.
  3. Драпкина О.М., Бойцов С.А., Омельяновский В.В., и др. Социально-экономический ущерб, обусловленный хронической сердечной недостаточностью, в Российской Федерации. Российский кардиологический журнал. 2021;26(6):4490 [Drapkina OM, Boytsov SA, Omelyanovskiy VV, et al. Socio-economic impact of heart failure in Russia. Russian Journal of Cardiology. 2021;26(6):4490 (in Russian)]. doi: 10.15829/1560-4071-2021-4490
  4. Shafie AA, Tan YP, Ng CH. Systematic review of economic burden of heart failure. Heart Fail Rev. 2018;23:131-45. doi: 10.1007/s10741-017-9661-0
  5. Mozaffarian D, Benjamin EJ, Go AS, et al. American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2016 Update: A report from the American Heart Association. Circulation. 2016;133:e38-60. doi: 10.1161/CIR.0000000000000350
  6. Недогода С.В., Лопатин Ю.М., Архипов М.В., и др. Фармако- эпидемиологический анализ рутинной практики ведения пациентов с хронической сердечной недостаточностью в Российской Федерации. Часть II. Российский кардиологический журнал. 2022;27(2):4759 [Nedogoda SV, Lopatin YuM, Arkhipov MV, et al. Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part II. Russian Journal of Cardiology. 2022;27(2):4759 (in Russian)]. doi: 10.15829/1560-4071-2022-4759
  7. КР 156/1. Хроническая сердечная недостаточность. Клинические рекомендации. 2020 г. Режим доступа: http://cr.rosminzdrav.ru/#!/recomend/134. Ссылка активна на 10.08.2023 [KR 156/1. Chronic heart failure. Clinical recommendations. 2020. Available at: http://cr.rosminzdrav.ru/#!/recomend/134. Accessed: 10.08.2023 (in Russian)].
  8. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063
  9. Jhund PS, Kondo T, Butt JH, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med. 2022;28:1956-64. doi: 10.1038/s41591-022-01971-4
  10. Недогода С.В., Терещенко С.Н., Жиров И.В., и др. Фармакоэкономический анализ применения лекарственного препарата дапаглифлозин у пациентов с хронической сердечной недостаточностью со сниженной фракцией выброса левого желудочка ≤40% II–IV функционального класса NYHA в Российской Федерации. Consilium Medicum. 2020;22(10):45-51 [Nedogoda SV, Tereshhenko SN, Zhirov IV, et al. Pharmacoeconomic analysis of the use of dapagliflozin in patients with NYHA class II–IV chronic heart failure with reduced left ventricular ejection fraction ≤40% in the Russian Federation. Consilium Medicum. 2020;22(10):45-51 (in Russian)]. doi: 10.26442/20751753.2020.10.200349
  11. National Institute of Health and Care Excellence. Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679). 2021. Available at: https://www.nice.org.uk/guidance/ta679. Accessed: 28.05.2023.
  12. Rutherford MJ, Lambert PC, Sweeting MJ, et al. NICE DSU Technical Support Document 21. Flexible Methods for Survival Analysis. 2020. Available at: http://www.nicedsu.org.uk. Accessed: 01.06.2023.
  13. Приказ Минздрава России от 20.04.2022 №272н «Об утверждении стандарта медицинской помощи взрослым при хронической сердечной недостаточности (диагностика, лечение и диспансерное наблюдение)». Режим доступа: http://publication.pravo.gov.ru/Document/View/0001202206020034. Ссылка активна на 10.08.2023 [Order of the Ministry of Health of Russia dated April 20, 2022 No. 272n “On approval of the standard of medical care for adults with chronic heart failure (diagnosis, treatment and clinical observation).” Available at: http://publication.pravo.gov.ru/Document/View/0001202206020034. Accessed: 10.08.2023 (in Russian)].
  14. Трансляция симпозиума «Новости ХСН – новые исследования и новые перспективы» в рамках Российского национального конгресса кардиологов 2022». Е.В. Шляхто (Санкт-Петербург). ХСН 2022: Реальная клиническая практика и наши ПРИОРИТЕТы. Режим доступа: https://www.youtube.com/watch?v=OTVMcvflg1Q. Ссылка активна на 10.08.2023 [Broadcast of the symposium “News of CHF – new research and new prospects” within the framework of the Russian National Congress of Cardiologists 2022.” EV Shlyakhto (St. Petersburg). CHF 2022: Real clinical practice and our PRIORITIES. Available at: https://www.youtube.com/watch?v=OTVMcvflg1Q. Accessed: 10.08.2023 (in Russian)].
  15. Постановление Правительства РФ от 29 декабря 2022 г. №2497 «О Программе государственных гарантий бесплатного оказания гражданам медицинской помощи на 2023 год и на плановый период 2024 и 2025 годов». Режим доступа: http://static.government.ru/media/files/FQATIOfojXIUYX8cwI2X7ugkeKRrRGjb.pdf. Ссылка активна на 10.08.2023 [Decree of the Government of the Russian Federation of December 29, 2022 No. 2497 “On the Program of State Guarantees for the provision of free medical care to citizens for 2023 and for the planning period of 2024 and 2025.” Available at: http://static.government.ru/media/files/FQATIOfojXIUYX8cwI2X7ugkeKRrRGjb.pdf. Accessed: 10.08.2023 (in Russian)].
  16. Мареев В.Ю., Фомин И. В., Агеев Ф. Т., и др. Клинические рекомендации ОССН-РКО-РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018;58(6S):8-158 [Mareev V Yu, Fomin I V, Ageev F T, et al. Russian Heart Failure Societyn Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Cardiology. 2018;58(6S):8-158 (in Russian)]. doi: 10.18087/cardio. 2475
  17. Тепцова Т.С., Мусина Н.З., Омельяновский В.В. Оценка референтного значения инкрементального показателя «затраты-эффективность» для российской системы здравоохранения. Современная фармакоэкономика и фармакоэпидемиология. 2020;13(4):367-76 [Teptsova TS, Musina NZ, Omelyanovsky VV. Evaluation of the reference value of the incremental parameter "cost-effectiveness" for Russian healthcare system. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020;13(4):367-76 (in Russian)]. doi: 10.17749/2070-4909/farmakoekonomika.2020.071
  18. Журавлева М.В., Терещенко С.Н., Жиров И.В., и др. Оценка эффективности затрат на предотвращение сердечно-сосудистой смерти и достижение целевого показателя «Снижение смертности населения от болезней системы кровообращения» Государственной программы «Развитие здравоохранения» при применении препаратов валсартан+сакубитрил, дапаглифлозин и эмпаглифлозин у пациентов с хронической сердечной недостаточностью со сниженной фракцией выброса левого желудочка. Российский кардиологический журнал. 2023;28(3):5386 [Zhuravleva MV, Tereshchenko SN, Zhirov IV, et al. Сost-effectiveness of preventing cardiovascular death and achieving the target indicator "Reduction of the cardiovascular mortality of the population" of the State Program "Health Development". Russian Journal of Cardiology. 2023;28(3):5386 (in Russian)]. doi: 10.15829/1560-4071-2023-5386
  19. Liao CT, Yang CT, Kuo FH, et al. Cost-effectiveness evaluation of add-on empagliflozin in patients with heart failure and a reduced ejection fraction from the healthcare system's perspective in the Asia-Pacific region. Front Cardiovasc Med. 2021;8:750381.
  20. Parizo JT, Goldhaber-Fiebert JD, Salomon JA, et al. Cost-effectiveness of dapagliflozin for treatment of patients with heart failure with reduced ejection fraction. JAMA Cardiol. 2021;6(8):926-35.
  21. Nguyen BN, Mital S, Bugden S, Nguyen HV. Cost-effectiveness of dapagliflozin and empagliflozin for treatment of heart failure with reduced ejection fraction. Int J Cardiol. 2023;376:83-9. doi: 10.1016/j.ijcard.2023.01.080
  22. Wu M, Qin S, Wang L, et al. Economic evaluation of dapagliflozin in the treatment of patients with heart failure: a systematic review. Front Pharmacol. 2022;13:1190.
  23. Cohen LP, Isaza N, Hernandez I, et al. Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors for the treatment of heart failure with preserved ejection fraction. JAMA Cardiol. 2023;8(5):419-28.
  24. Sandhu AT, Cohen DJ. Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Patients With Heart Failure and Preserved Ejection Fraction–Living on the Edge. JAMA Cardiol. 2023;8(5):415-6. doi: 10.1001/jamacardio.2023.0087

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Model structure of the pattern of chronic heart failure.

Download (107KB)
Indexing metadata
3. Fig. 2. Tornado diagram.

Download (150KB)
Indexing metadata

Copyright (c) 2023 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies